Aflibercept formulations and uses thereof

An ophthalmic formulation, comprising:

• (a) aflibercept in a concentration of 5-100 mg/mL;
• (b) a histidine buffer, wherein the histidine buffer concentration is 5-50 mM;
• (c) a non-ionic surfactant selected from the group consisting of a polysorbate, a polyethylene glycol dodecyl ether, a poloxamer, 4-(1,1,3,3-Tetramethylbutyl)phenyl-polyethylene glycol, an alkylsaccharide and an alkylglycoside, at a concentration of 0.001% (w/v) to 5% (w/v);
• (d) a tonicifying agent comprising a polyol or an amino acid selected from proline, arginine, aspartate, glutamate, glycine, histidine, isoleucine, and lysine, at a concentration of 2-4% (w/v), wherein the formulation has a final osmolality of 300±50 mOsm/kg;
• (e) an additional amino acid stabilizing agent selected from the group consisting of proline, arginine, methionine, lysine and mixtures thereof;
• and
• wherein the pH of the formulation is about pH 5.0 to about pH 6.5.